In the past year (12/1/2008-11/30/2009), 326 patients were registered onto 26 high priority, innovative, feasibility (i.e., pre-phase I, pilot) and phase 1 institutional clinical interventions. These studies reflect the efforts of 19 different OSUCCC principal investigators (Table 2) and the scientific activities of four OSUCCC programs;Experimental Therapeutics (ETP), Cancer Control (CC), Molecular Carcinogenesis and Chemoprevention (MCC) and Immunology (IMM). Patients enrolled onto these protocols are managed by the Clinical Trials Office (CTO) utilizing protocol-specific-clinical research support. Based upon the current accrual statistics for investigator-initiated therapeutic clinical trials and an estimate of approximately 40 active clinical trial participants per clinical coordinator per year, we can justify a request for 5.0 FTEs for protocol-specific clinical support in year one of the CCSG renewal (see justification above). The CTO now manages 365 open clinical trials, including 55 therapeutic trials that were authored by OSUCCC investigators. Clinical investigators at the OSUCCC are encouraged to actively pursue funding for trials through external peer review mechanisms whenever possible. Thus, a number of these investigator-initiated trials (12) are supported though the OSU phase 1 grant (UOl CA76576) or the OSU NOI grant {m^ CM62207). Trials that are not supported by external funds are eligible for Protocol-Specific Research Support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601840
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$212,584
Indirect Cost
$73,184
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Madan, Esha; Parker, Taylor M; Bauer, Matthias R et al. (2018) The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. J Biol Chem 293:4262-4276

Showing the most recent 10 out of 2602 publications